INNT
TOTAL INVALIDATION PROCESSED BY THE IB
04/26/2025
Back to search
Official data from USPTO
CAP GT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CAP GT
ST13
US500000079197642Class
1, 5, 42
Filing
79197642
Registration
5319386
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
49
Latest update
04/27/2025
Trademark type
Word
Nice classes
1, 5, 42
Filing date
07/11/2016
Registration date
10/31/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/17/2024
Last transaction
04/27/2025
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
27
Owner location
DE
Examiner
CORWIN, KEVIN
Law office
M30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
CEVEC Pharmaceuticals GmbH
Representatives
Miriam D. Trudell Sheridan Ross P.C.
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiological and biochemical productspreparations and reagents for scientificresearchlaboratoryindustrial and commercial purposesexcept chromatography chemicals and mediaexcept chemicals for use in separation and purification; chemicalbiological and biochemical productspreparations and reagents for researching and characterizing diseases except chromatography chemicals and mediaexcept chemicals for use in separation and purification; chemicalbiological and biochemical productspreparations and reagents for scientific and medical research and drug development except chromatography chemicals and mediaexcept chemicals for use in separation and purification; chemicalbiological and biochemical productspreparations and reagents for manufacturing drugs and pharmaceuticalsexcept chromatography chemicals and mediaexcept chemicals for use in separation and purification; micro-organismsproteinspolypeptidesnucleotidesnucleic acidseukaryotic cell lines and eukaryotic cells for scientificresearchlaboratoryindustrial and commercial purposes; all other than for medical or veterinary use
Class 5
Medicines for the treatment and prevention of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseasesexcept thyreostatics and cough and cold preparations; pharmaceutical and veterinary productspreparations and reagents for the treatment and prevention of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseasesall afore mentioned goods except thyreostatics and cough and cold preparations; chemicalbiological and biochemical preparations for the treatment and prevention of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseasespreparations and reagents for medical and veterinary purposes for the treatment and prevention of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseasesexcept cough and cold preparationsexcept chromatography chemicals and mediaexcept chemicals for use in separation and purification; diagnostic and analytical preparations for medical and veterinary purposes for the treatment and prevention of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseases; cultures of micro-organismsprotein arrayssynthetic polypeptidesnucleotide arraysnucleic acid sequenceeukaryotic cell lines and eukaryotic cells for medicalveterinary and diagnostic purposesexcept cough and cold preparations
Class 42
Scientific and industrial researchin particular in the fields of medicinepharmacymolecular biologybiotechnology and genetics; research and development of drugsdiagnostic and analytical preparationstherapy procedures and expression systems; scientifictechnical and industrial consultancyin particular in the field of research medicinepharmacymolecular biologybiotechnology and genetics; scientific and industrial research and development of eukaryotic cell lineseukaryotic cellsmicro-organismspolypeptidesproteinsnucleotidesnucleic acidsfor third parties for scientificresearchlaboratory developmentindustrial and commercial purposesin particular for use in the field of medicinepharmacymolecular biologybiotechnology and geneticsexcept services relating to capture and intermediate purification of proteins
Publications
History of USPTO decisions and trademark events.
49 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
04/06/2025
INPC
INVALIDATION PROCESSED
04/05/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
01/18/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/18/2024
C71T
CANCELLED SECTION 71
05/17/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/19/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/21/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
08/21/2023
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
08/21/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/21/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/21/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/21/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/21/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/31/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/13/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
07/13/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/13/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/13/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/11/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
06/11/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/11/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/11/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/17/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/30/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/06/2018
FIMP
FINAL DISPOSITION PROCESSED
02/06/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/31/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/27/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
10/31/2017
GPNX
NOTIFICATION PROCESSED BY IB
08/18/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/15/2017
PUBO
PUBLISHED FOR OPPOSITION
08/15/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/02/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/02/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/26/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/11/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/13/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/13/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/13/2017
RFNT
REFUSAL PROCESSED BY IB
01/20/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/30/2016
RFRR
REFUSAL PROCESSED BY MPU
12/30/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/28/2016
CNRT
NON-FINAL ACTION WRITTEN
12/27/2016
MAFR
APPLICATION FILING RECEIPT MAILED
12/20/2016
DOCK
ASSIGNED TO EXAMINER
12/15/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/15/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/08/2016
Continuous trademark protection
Get notified about every new filing that threatens CAP GT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.